文献速递其他结缔组织病

年轻anti-HMGCR肌病患者的疾病更重且恢复更慢

More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.
PubMed 文献 · Rheumatology (Oxford) · 2017-01-01

该研究纳入anti-HMGCR阳性患者,评估肌力、肌酸激酶及治疗,发现50例随访≥2年者中仅44%经免疫抑制治疗达完全肌力,且年轻发病者疾病更重、恢复更慢、难治比例更高。

要点

  • 随访≥2年的50例中仅22例(44%)达完全肌力。
  • 达完全肌力者中55%肌酸激酶仍>500 IU/l。
  • 发病年龄较大者各时间点肌力更强且改善更快。

核心结论

  • anti-HMGCR肌病通常为慢性病,需要长期免疫抑制治疗。
  • 年轻患者疾病更重、预后更差,但未发现已知肌营养不良的致病突变。

研究设计与样本

  • 在anti-HMGCR阳性患者每次临床访视时评估肌力、肌酸激酶水平和治疗。
  • 采用单因素和多因素分析临床特征对肌力及肌力变化的影响,并对部分患者行全外显子测序。

主要发现

  • 50例随访≥2年的患者中仅22例(44%)经免疫抑制治疗达到完全肌力。
  • 达到完全肌力的患者中55%肌酸激酶水平仍超过500 IU/l,仅3例能停用免疫抑制治疗。
  • 单因素和多因素分析显示发病年龄较大者各时间点肌力更强(P < 0.001)且改善更快(P < 0.008)。
  • 他汀暴露史与改善速率无独立关联,年轻患者更易患难治性疾病(P = 0.02)。
  • 8例可检测DNA的难治患者全外显子测序未发现已知肌营养不良基因的致病突变,且癌症风险未较一般人群增加。

关键数值与推荐

  • 完全肌力:50例中22例(44%)达到。
  • 肌酸激酶升高:达完全肌力者中55%仍>500 IU/l。
  • 发病年龄较大与肌力更强相关(P < 0.001),与改善更快相关(P < 0.008)。
  • 年轻患者难治性疾病风险更高(P = 0.02)。

临床怎么用

  • anti-HMGCR肌病常需长期免疫抑制治疗,应预期缓慢且不完全的肌力恢复。
  • 年轻发病者应警惕难治性疾病,加强监测与治疗调整。
  • 达到完全肌力后仍需关注持续升高的肌酸激酶,停用免疫抑制需谨慎。

局限性

  • 全外显子测序仅在8例难治患者中进行,样本量有限。
  • 原文未报告研究设计类型、检索范围或指南推荐等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study disease severity and response to therapy in a large cohort of patients with anti-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR)-associated myositis. METHODS: Muscle strength, creatine kinase levels and treatments were assessed in anti-HMGCR-positive patients at each clinical visit. Univariate and multivariate analyses were used to analyse the influence of clinical characteristics on strength and the change in strength over time. Whole exome sequencing was performed in a subset of patients. RESULTS: . Among 50 patients followed for ⩾2 years, only 22 (44%) reached full strength with immunosuppressive therapy; even among those with full strength, 55% continued to have CK levels in excess of 500 IU/l and only three could be tapered off immunosuppressive therapy. Both univariate and multivariate analysis showed that patients who were older at disease onset were stronger at all time points (P < 0.001) and improved faster (P < 0.008) than younger patients; a history of statin exposure was not independently associated with the improvement rate. Younger patients were more likely to have refractory disease (P = 0.02) than older patients. Among eight refractory patients with DNA available for testing, whole exome sequencing did not reveal pathogenic mutations in known dystrophy genes. The risk of cancer was not increased in anti-HMGCR myositis patients compared with the general population. CONCLUSIONS: Anti-HMGCR myositis is usually a chronic disease requiring long-term immunosuppression. Although younger patients had more severe disease and a worse prognosis than older patients, they did not have evidence of a known co-existing muscular dystrophy to explain their persistent, and sometimes progressive, muscle weakness.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Tiniakou E, Pinal-Fernandez I, Lloyd TE, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford). 2017. PMID: 28096458. doi:10.1093/rheumatology/kew470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。